Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World October 14, 2009 Phil Taylor	Tracing amyloid in Alzheimer's A diagnostic compound that allows researchers to look into the brains of Alzheimer's patients will be used for the first time to gauge the effects of an experimental therapy for the disease.
Chemistry World December 21, 2006 Tom Westgate	Molecular Probe Identifies Patients at Risk of Alzheimer's A new molecule could provide an early warning system for Alzheimer's disease, US researchers hope.
Chemistry World November 3, 2011 David Bradley	Faster Synthesis of Fluorine Radioisotope Imaging Agents A palladium-containing fluorination reagent can be used to quickly synthesise aromatic molecules labelled with fluorine-18, a positron emitter used in molecular imaging.
Chemistry World July 20, 2012 Michael Parkin	New supramolecular Alzheimer's drugs Supramolecular chemistry could provide a new avenue in the treatment of Alzheimer's disease, say scientists in China.
AskMen.com Jacob Franek	Alzheimer's Disease 101 It's only in the last decade or so that we have truly come to understand the various disorders of the brain that are associated with age and, in most cases, Alzheimer's disease is the prime suspect. Read on for some basic information.
BusinessWeek July 15, 2010 Lopatto & Matsuyama	The Race for Diagnostic Tests for Alzheimer's GE, Bayer, and Avid are vying to be first to market an early test for Alzheimer's.
Chemistry World February 7, 2011 Carl Saxton	Targeting memory loss A new treatment for Alzheimer's disease has been developed by Canadian and US scientists.
Chemistry World February 11, 2011 David Barden	Waking up to new possibilities in imaging UK researchers have used a cage-like molecule to smuggle metal ions into cells, which could improve medical imaging.
Chemistry World August 24, 2010 Lewis Brindley	A better way to add radioactive fluorine Making compounds that contain the useful radioisotope fluorine-18 ( 18F) could be much easier in future, say researchers in the UK and Finland.
Reactive Reports October 2006 David Bradley	Drink Up! Lest We Forget There is potentially good news for red wine lovers whose favorite tipple is Cabernet Sauvignon. Researchers have found that moderate consumption of Cabernet Sauvignon can attenuate neural degradation in laboratory mice with Alzheimer's disease.
Chemistry World June 14, 2009 Hayley Birch	New technique probes Alzheimer's aggregates US and UK researchers have used a new technique to identify what they think could be the primary toxic species in the development of Alzheimer's disease
Chemistry World July 22, 2009 Phil Taylor	New drug turns Alzheimer's theory on its head Researchers have been left puzzled by data showing that the antihistamine dimebolin, a drug with promising activity in improving Alzheimer's symptoms, actually seems to increase levels of the toxic protein beta amyloid.
Chemistry World July 3, 2014 Maria Burke	Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK.
The Motley Fool August 17, 2010 Brian Orelli	Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.
The Motley Fool January 12, 2005 Charly Travers	Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity.
The Motley Fool February 3, 2004 David Nierengarten	Big Break for a Small Biotech? Axonyx's new drug for Alzheimer's disease could be first in its class.
Managed Care December 2005 David S. Geldmacher	The Cost Benefit to Health Plans of Pharmacotherapy for Alzheimer's Disease As with other chronic diseases of aging, early diagnosis and pharmacologic therapy may reduce the costs for enrollees with Alzheimer's disease. This article reviews patient and caregiver outcomes associated with reduced health care costs and their implications for Managed Care Organizations.
The Motley Fool January 19, 2011 Brian Orelli	High Stakes at Tomorrow's FDA Panel Meeting It's more than just Eli Lilly on the line.
Nurse Practitioner August 2011 Davis et al.	Supportive approaches for Alzheimer Disease Alzheimer disease accounts for almost 80% of all dementia diagnoses. Currently, more than 5 million Americans suffer from this debilitating illness, with the highest prevalence in the oldest age groups.
Chemistry World July 30, 2008 Sarah Houlton	A metal trap to stop Alzheimer's Trapping metals could prove a key to curing Alzheimer's disease, according to the promising results of early clinical trials on a compound called PBT2.
Chemistry World September 20, 2012 Jessica Cocker	Biological fate of nanoparticles in the body Nanoparticles are extremely difficult to detect and measure once they are distributed in a biological system. Now, Spanish scientists have developed a novel way for measuring their biodistribution.
Chemistry World August 24, 2006 Jessica Ebert	Alzheimer's Researchers Tackle Waste Disposal The memory of mice with Alzheimer's-like symptoms is improved by inoculating the mice with an enzyme involved in protein degradation, report US researchers. The work could lead to new therapies for patients with Alzheimer's disease.
Chemistry World November 20, 2013 Rebecca Brodie	Therapeutic screening for Alzheimer's disease Scientists in Canada and the US hope a system they have developed for monitoring amyloid- aggregation on a chip could be used to find new treatments for Alzheimer's disease.
The Motley Fool January 17, 2012 Brian Orelli	You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again.
BusinessWeek January 8, 2007 Catherine Arnst	Decoding Alzheimer's After a century, promising treatments at last - and whispers of a cure.
The Motley Fool February 8, 2005 Charly Travers	Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company
HHMI Bulletin May 2010 Lauren Gravitz	Live Long and Prosper Mix amyloid plaques with longevity and you get mice that not only live longer, but healthier too.
Chemistry World September 21, 2006 Michael Gross	Alzheimer's Alphabet Alzheimer's researchers are now closer to understanding the natural function of one of the two enzymes that cut A out of APP, and have recreated the process by which fibril formation begins in vivo.
American Family Physician March 1, 2003	Memory Loss Why am I losing my memory?... Where Can I Get More Information?... Memory Problems that Are Not Part of Normal Aging... What about when I know a word but cannot recall it?... How can I tell if my memory problems are serious?... etc.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Alzheimer's: A Disease at a Crossroads The need for new drugs intensifies as more and more Baby Boomers live into advanced old age. The global market is estimated to be worth $20 billion by the end of the decade.
IEEE Spectrum April 2013 Neil Savage	Path Found to a Combined MRI and CT Scanner Omni-tomography could add together the advantages of several medical imaging technologies
Pharmaceutical Executive August 1, 2008 Patrick Clinton	Salute to the Murines What can we say about modern medicine? The answer, of course, is that it's brilliant at curing the ailments of mice.
Chemistry World January 3, 2007 Victoria Gill	Alzheimer's Protein Fingerprint Alzheimer's disease, a debilitating neurodegenerative disorder that eventually results in wasting of the whole brain, offers a chemical clue that should make it easier to spot and possibly easier to treat.
Chemistry World August 9, 2012	Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials.
Chemistry World June 12, 2007 Simon Hadlington	A New Way to Look at the Brain Researchers have for the first time scanned the human brain with positron emission tomography and magnetic resonance imaging simultaneously. The work introduces the possibility of obtaining both highly specific functional data together with anatomical information in a single scan.
Chemistry World November 2, 2006 Michael Gross	Alzheimer's Century Researchers worldwide are commemorating the centenary of Alois Alzheimer's first description of the dementia named after him.
AskMen.com Jacob Franek	Future Cures Almost every disease known to man is under constant research and we can hardly go a day without hearing about some advancement or another. Here are a few diseases for which future cures could be looming on the horizon.
Chemistry World November 7, 2011 Kate McAlpine	Spotting Artery Damage Before a Heart Attack An international team of medical researchers has developed a way to perform a check up on an artery's physical structure and molecular markers of ill health by coupling a catheter with imaging technology.
Chemistry World January 10, 2014 Jennifer Newton	Heather Williams: Science is for everyone Heather Williams is a medical physicist at Central Manchester University Hospitals who specializes in positron emission tomography. She is also an advocate for women in science.
Managed Care July 2006 Lola Butcher	Oncologic PET Study Seeks Basis for Coverage Decisions The launch of a new registry that will significantly expand Medicare's coverage of positron emission tomography may bring new clarity on appropriate uses for this technology -- and even more pressure on commercial health plans to cover the high-cost scans.
Registered Rep. August 30, 2011 Amy Burroughs	When Your Client Has Alzheimer's One early sign of the disease is trouble managing money, which puts financial advisors on the front lines.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
The Motley Fool November 26, 2007 Brian Lawler	Biogen Plays Deal Maker Biogen Idec signs a drug development deal with Swiss-based Neurimmune Therapeutics worth up to $380 million. Investors, take note.
Salon.com August 29, 2001 Pam Rosenthal	"The Forgetting" by David Shenk A brilliant and quirky new book on Alzheimer's offers food for thought on the unthinkable and a new, deeper understanding of the coming epidemic.
American Family Physician November 1, 2000 Monica Preboth	Clinical Briefs Sports Specialization in Young Athletes... ADA Statement on Nutrition in Diabetes... Diagnostic Imaging to Detect Child Abuse... NIH/NIA Report on Alzheimer's Disease... CDC Report on U.S. Incidence of Measles in 1999... Managing Pain and Stress in the Neonate...